Pay in 4 interest-free payments of $6.82 Learn more
Ships within 48 hours · Estimated delivery Aug 8 - Aug 13
In a rigorous 6-week, double-blind, placebo-controlled clinical trial published in the Aesthetic Surgery Journal Open Forum, DermaReverse demonstrated remarkable results among GLP-1 users: 100% of participants experienced an improvement in wrinkle appearance 100% experienced an improvement in surface roughness 100% experienced a reduction in redness 100% experienced an improvement in hydration 100% agreed DermaReverse was gentle enough for daily use These results were verified by independent board-certified plastic surgeons and third-party independent medical journal reviewers, establishing DermaReverse as not just another skincare product, but a clinically validated treatment specifically addressing the unique skin concerns of GLP-1 users
The number of melanocytes (pigment-generating cells) decreases, causing the skin's antioxidant system to drop
2009 Nov;18(11):29748
Tirzepatide is a glucose-dependent insulinotropic polypeptide/GLP- 1 dual receptor agonist (GIP/GLP- 1 RA) and in the Phase 3 SURMOUNT- 1 trial, tirzepatide 5 mg, 10 mg and 15 mg produced mean weight reduction from baseline to week 72 of 15,0%, 18.5% and 20.9%, respectively, versus 2.4% for placebo
Pharmaceutical-grade solutions that are 10-15 times more effective at absorption than regular glutathione powder have been made by companies like Shaanxi Hongda Phytochemistry Co., Ltd., using advanced nano-encapsulation techniques
